FDA Takes Action on Compounded GLP-1 Drugs
The U.S. Food and Drug Administration (FDA) has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, a move that could significantly affect the large-scale compounding of these popular GLP-1 medications.
The agency announced the proposal after determining that outsourcing facilities do not have a clinical need to compound these drugs from bulk substances. The FDA stated that approved versions of these medications are currently available, eliminating the need for compounded alternatives under existing regulations.
Understanding the 503B Bulks List
The 503B Bulks List identifies drug substances that FDA-registered outsourcing facilities may use when compounding medications. Under federal law, these facilities generally cannot compound drugs using bulk substances unless the ingredient appears on the 503B Bulks List or the drug is listed on the FDA’s drug shortage database.
Consequently, removing semaglutide, tirzepatide, and liraglutide from consideration would further limit the circumstances under which outsourcing facilities can produce compounded versions of these medications.
FDA Finds No Clinical Need
After reviewing nominations and available evidence, the FDA concluded that sufficient clinical need does not exist for outsourcing facilities to compound these drugs from bulk ingredients.
As per FDA.gov news release, the agency carefully evaluated the submissions it received and found no evidence supporting the inclusion of semaglutide, tirzepatide, or liraglutide on the 503B Bulks List. The FDA emphasized that decisions regarding clinical need must align with patient safety requirements and medical necessity standards established under federal law.
Furthermore, FDA Commissioner Marty Makary stated that outsourcing facilities cannot lawfully compound drugs from bulk substances when FDA-approved alternatives are available unless a clear clinical need exists.
Potential Impact on the Compounding Industry
If finalized, the proposal could reduce large-scale compounding of GLP-1 medications by 503B outsourcing facilities. However, the proposal primarily affects outsourcing facilities rather than traditional 503A compounding pharmacies that prepare medications for individual patients based on specific prescriptions.
Moreover, the decision may have implications for telehealth providers, weight-loss clinics, and other healthcare businesses that have relied on compounded GLP-1 medications supplied by outsourcing facilities.
Public Comment Period Now Open
The FDA has opened a public comment period and is inviting stakeholders to submit feedback on the proposal. Interested parties can provide comments until June 29, 2026, before the agency makes a final determination.
Meanwhile, healthcare providers, patients, compounding pharmacies, and industry groups are expected to closely monitor the regulatory process and its potential impact on access to GLP-1 therapies.
Looking Ahead
The FDA’s proposal marks another significant development in the regulation of compounded GLP-1 medications. While the agency has not yet issued a final decision, the proposal signals its position that FDA-approved versions of semaglutide, tirzepatide, and liraglutide adequately meet current clinical needs. The final outcome will depend on the agency’s review of public comments and further regulatory evaluation.